思覺失調症藥物市場規模、佔有率、成長分析、按藥物類別、按治療、按分銷管道、按地區 - 行業預測，2024-2031 年

2022年全球思覺失調症藥物市場規模為75億美元，從2023年的79億美元成長到2031年的119.4億美元，複合年成長率預計將維持在5.3%。

思覺失調症對生活的許多重要領域產生重大影響，包括人際關係、家庭關係、教育和就業，並且與過早死亡的風險增加有關，比一般人高兩到三倍。此病影響全球約2,400萬人，佔人口的0.32%，成人盛行率高達0.45%。尤其是，此病在男性的發生率是女性的1.4倍，發病高峰年齡為男性20至28歲，女性25至32歲。由於有利的醫療改革、人口老化、健康意識的提高、具有成本效益的解決方案等，印度和中國的新興市場為思覺失調症藥物市場提供了巨大的成長機會。這種成長軌跡在亞太地區尤其明顯，儘管存在挑戰，包括低度開發地區缺乏知名度，阻礙了市場擴張。同時，美國思覺失調症藥物市場預計在即將到來的預測期內將保持持續的複合年成長率。這些見解為思覺失調症治療領域的相關人員帶來了光明的前景，在全球不同程度的意識和準備情況下提供了創新和擴大影響力的途徑。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• PESTEL分析
• 價格分析

思覺失調症藥物市場：依藥物類別

• 市場概況
• 第二代抗精神病藥
  • Risperdal（Risperidone）
  • Invega（帕潘立酮）
  • Zyprexa（Olanzapine）
  • Geodon（齊拉西酮）
  • Seroquel（Quetiapine）
  • 拉圖達（Lurasidone）
  • Aristada（Aripiprazole哌唑）
  • Fanapt（Iloperidone）
  • 薩弗里斯（Asenapine）
  • Vreilor（Cariprazine）
• 第三代抗精神病藥
  • Abilify（Aripiprazole）
• 其他
  • 第一代抗精神病藥
  • 非專利的

思覺失調症藥物市場：依治療分類

• 市場概況
• 口服抗精神病藥
• 注射抗精神病藥

思覺失調症管道

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

思覺失調症藥物市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Johnson & Johnson（US）
• Bristol-Myers Squibb（US）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• AstraZeneca（UK）
• Sumitomo Dainippon Pharma（Japan）
• Eli Lilly and Company（US）
• Alkermes Plc（Ireland）
• Vanda Pharmaceuticals Inc.（US）
• Allergan（Ireland）
• Pfizer Inc.（US）
• H. Lundbeck A/S（Denmark）
• Janssen Pharmaceuticals, Inc.（US）
• Minerva Neurosciences（US）
• Reliance Life Sciences（India）
• Novartis AG（Switzerland）
• GlaxoSmithKline（UK）
• Merck KGaA（Germany）
• Takeda Pharmaceuticals（Japan）
• AbbVie（US）
• Acadia Pharmaceuticals（US）
• Karuna Therapeutics（US）

Global Schizophrenia Drugs Market size was valued at USD 7.50 billion in 2022 and is poised to grow from USD 7.90 billion in 2023 to USD 11.94 billion by 2031, growing at a CAGR of 5.3% in the forecast period (2024-2031).

Schizophrenia significantly impacts various critical areas of life, including personal relationships, family dynamics, education, and employment, leading to a heightened risk of premature death-two to three times higher than the general population. The condition affects approximately 24 million people globally, translating to 0.32% of the population, with a higher prevalence of 0.45% among adults. Notably, the disorder occurs 1.4 times more frequently in men than women, with peak onset ages ranging from 20 to 28 years for males and 25 to 32 years for females. Emerging markets in India and China present substantial growth opportunities for the schizophrenia drug market, driven by favorable healthcare reforms, an aging population, increasing health awareness, and cost-effective solutions. This growth trajectory is particularly strong in the Asia Pacific region, despite challenges such as a lack of awareness in underdeveloped areas hindering market expansion. Meanwhile, the US schizophrenia drug market is projected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast period. These insights indicate a promising landscape for stakeholders in the schizophrenia treatment sector, offering avenues for innovation and expanded reach amidst varying global awareness and preparedness levels.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Schizophrenia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Schizophrenia Drugs Market Segmental Analysis

Global Schizophrenia Drugs Market is segmented on the drug class, treatment, distribution channel and region. By drug class, market is segmented into second-generation antipsychotics, third-generation antipsychotics, and others. By treatment, market is segmented into oral antipsychotics, and injectable antipsychotics. By distribution channel, market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is poised for significant growth, driven by an increasing prevalence of schizophrenia and an escalating demand for improved healthcare infrastructure. As governments partner with healthcare facilities to enhance treatment safety and availability, more patients are receiving adequate therapeutic interventions. Ongoing clinical studies aimed at developing innovative drugs targeting novel molecular pathways are set to address pressing unmet needs in schizophrenia management. This proactive approach by pharmaceutical companies to explore new therapeutic avenues and strengthen their drug pipelines is expected to captivate both healthcare providers and patients, thus propelling the market forward.

Restraints in the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market faces significant restraints that hinder its growth potential. A critical barrier is the insufficient awareness and understanding of mental health issues, particularly in developing countries, where stigma and lack of resources further complicate treatment accessibility. Furthermore, the high costs associated with schizophrenia medications and treatments limit patient access and reduce overall market demand. Additionally, adverse effects associated with many antipsychotic medications contribute to patients' reluctance to initiate or adhere to treatment regimens, undermining confidence in available therapies. Together, these factors create a challenging landscape that slows the overall expansion of the market.

Market Trends of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is experiencing a transformative shift driven by an evolving understanding of the complex mechanisms underlying schizophrenia. With traditional views focusing on dopamine dysregulation now expanded to include multifaceted structural and chemical abnormalities, drug development is increasingly targeting novel pathways. Research is gaining momentum in exploring trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors, which promise to offer safer and more effective therapeutic options. This diversification in targets is paving the way for innovative treatments, thus propelling market growth as pharmaceutical companies adapt to these advancements and strive to meet the evolving needs of patients globally.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• PESTEL Analysis
• Pricing Analysis

Schizophrenia Drugs Market, By Drug Class

• Market Overview
• Second-Generation Antipsychotics
  • Risperdal (Risperidone)
  • Invega (Paliperidone)
  • Zyprexa (Olanzapine)
  • Geodon (Ziprasidone)
  • Seroquel (Quetiapine)
  • Latuda (Lurasidone)
  • Aristada (Aripiprazole Lauroxil)
  • Fanapt (Iloperidone)
  • Saphris (Asenapine)
  • Vraylar (Cariprazine)
• Third-Generation Antipsychotics
  • Abilify (Aripiprazole)
• Others
  • First-Generation Antipsychotics
  • Generics

Schizophrenia Drugs Market, By Treatment

• Market Overview
• Oral Antipsychotics
• Injectable Antipsychotics

Schizophrenia Drugs Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Schizophrenia Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minerva Neurosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karuna Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments